Learn about the latest treatments for advanced ovarian cancer. We’ve got it covered, from new FDA approvals to emerging approaches in immunotherapy, targeted therapy, cancer vaccines, drug combinations, antibody-drug conjugates, and more.

  • June 8, 2020 

    New Treatments for Ovarian Cancer in 2020

    Smruti Vidwans, PhD

    Women with ovarian cancer once relied solely on chemotherapy to treat their disease. However, in recent years, treatment options have expanded, and new options are also on the horizon. Read on to learn more about ovarian cancer and how it… Read more »

  • September 1, 2020 

    Ovarian Cancer—An Overview (2020)Bookmark

    George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Medscape has published this excellent, authoritative, comprehensive overview of ovarian cancer, which includes information on diagnosis and treatment. (Written with a physician audience in mind.)

    .

  • August 7, 2020 

    Clinical Challenges: Platinum-Resistant Ovarian CancerBookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    Chemotherapy in the form of a single drug (as opposed to a combination of drugs) remains the best treatment for relapsed, platinum-resistant, serous, epithelial ovarian cancer. However, clinical trials are exploring new targeted therapy and immunotherapy options for this disease.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 7, 2020 

    FDA Approves Merck’s Keytruda, Foundation Medicine CDx for TMB-High Solid TumorsBookmark

    George Lundberg, MD

    Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

    Go to full article published by GenomeWeb.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020 

    Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian CancerBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 2, 2020 

    FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian CancerBookmark

    George Lundberg, MD

    Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

    This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.

    Go to full article published by the FDA.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • Show More
Dr. Rahib is extremely helpful and I am very thankful to have access to such professional and state-of-the-art support.

Ines
Daughter of pancreatic cancer patient

Molecular tests help match patients to the personalized treatments that are most likely to work for them. Keep up with new developments in genetic tests, blood tests, liquid biopsies, tumor mutations, other biomarkers, precision medicine, and next-generation sequencing.

Some of the most promising new treatments for advanced ovarian cancer are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.

What if your doctor could know what everyone collectively knew?

Marty Tenenbaum, PhD
Founder of Cancer Commons

Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.

  • October 14, 2019 

    Pediatric Palliative Care: A Specialty Comes of Age

    Sarah Friebert, MD

    For a child with cancer, palliative care can provide much-needed relief from stress and symptoms—for the patient and their family alike. Palliative care is given alongside cancer treatment, and is not synonymous with “end-of-life” care. In fact, anyone with a… Read more »

  • February 11, 2020 

    ‘Impressed With Impact’ of Ketamine in Cancer Palliative CareBookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • October 7, 2019 

    Emphasizing Oncogeriatrics

    With: Nicolò Matteo Luca Battisti, MD

    A Q&A with Nicolò Matteo Luca Battisti, MD, Medical Oncologist at The Royal Marsden NHS Foundation Trust, London, United Kingdom, and Chair of the Young Interest Group of the International Society of Geriatric Oncology (SIOG); nicolo.battisti@gmail.com Q: Everyone knows that… Read more »

  • December 3, 2018 

    Best Uses of Physical Medicine and Rehabilitation in Patients with Cancer

    With: Val Jones, MD

    A Q&A with Val Jones, MD, Medical Director of Admissions, Saint Luke’s Rehabilitation Institute, Spokane, WA Originally published February 1, 2017 Q: Your principal practice in Spokane, Washington is physical medicine and rehabilitation (PM&R). What do you find to be… Read more »

  • September 14, 2018 

    Huge Progress in Palliative Care

    With: Diane E. Meier, MD, FACP

    A Q&A with Diane E. Meier, MD, FACP, Director, Center to Advance Palliative Care; Professor of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai; New York, NY; diane.meier@mssm.edu Originally published November 8, 2017 Q: You wrote in… Read more »

  • July 23, 2018 

    Cancer Pain and the Opioid Epidemic

    George Lundberg, MD

    A Q&A with Kevin Sevarino, MD, PhD, President-elect of the American Academy of Addiction Psychiatry and Consulting Psychiatrist at Gaylord Hospital in Wallingford, CT Q: Opioid abuse, addiction, and overdose are huge American problems right now. Many cancer patents experience chronic… Read more »

    • Show More

You’re not alone. Read how other patients and caregivers navigated diagnosis, treatment, and life with cancer. We hope their stories provide insights and hope for your own cancer journey.

More patient stories

Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.

  • November 10, 2020 

    How to Learn About Cancer in a Classroom: Shaping Compassionate Doctors

    With: Marin Langlieb

    The patients and caregivers we serve here at Cancer Commons rely on their doctors to provide expert, compassionate care. Building the skills to give such care can begin early in a doctor’s education. Here, for a change of pace, our… Read more »

  • September 9, 2020 

    Is Cancer the Best Way to Die?

    With: Richard Smith, CBE, FMedSci

    In 2014, the prestigious medical research journal The BMJ published a controversial piece called “Dying of cancer is the best death.” Here, our Curious Dr. George asks the author of that piece, Richard Smith, CBE, FMedSci, if and how his thoughts… Read more »

  • August 21, 2020 

    The Power of Precision Medicine is Exemplified by Tempus

    With: Nike Beaubier, MDNamratha Sastry, PhD

    Tempus—a tech company & partner of Cancer Commons—empowers doctors to make data-driven decisions for their patients in real time. Learn how.

  • June 29, 2020 

    Cancer Screening Programs Influence Incidence and Causes of Cancer DeathsBookmark

    Lola Rahib, PhD

    Article from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.

    In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.

    Go to full article published by ASCO Daily News.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020 

    What Have I Learned in More Than Half a Century in Cancer Medicine?Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    “Patients with cancer need to be embraced with love and compassion. They need caring beyond medicine.”

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • April 27, 2020 

    The Challenges of Using Artificial Intelligence to Improve Cancer Treatment

    With: Razelle Kurzrock, MDJeff Shrager, PhD

    In a previous post, CureMatch co-founder Razelle Kurzrock, MD, told us all about her company’s artificial intelligence (AI) platform that matches patients with treatments based on their cancer’s molecular profile. Here, AI expert Jeff Shrager, PhD, responds, and Kurzrock offers… Read more »

    • Show More

The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.